Navigation Links
Perrigo Reports Record Revenue and Adjusted Earnings
Date:5/7/2013

949498,74413,505

(a)

485,23918 %17 %Gross profit

331,36120,515351,876279,27313,505292,77819 %20 %Operating expensesDistribution

12,569-12,56910,181-10,18123 %23 %Research and development

28,526-28,52627,950-27,9502 %2 %Selling and administration

111,6609,078

(a,c)

102,58287,9915,027

(a)

82,96427 %24 %Restructuring

---7,0817,081

(e)

---Total operating expenses

152,7559,078143,677133,20312,108121,09515 %19 %Operating income

178,60629,593208,199146,07025,613171,68322 %21 %Interest, net

16,070-16,07016,651-16,651-3 %-3 %Other expense (income), net

841-841(5,202)-(5,202)--Loss on sale of investment

1,6081,608------Income before income taxes

160,08731,201191,288134,62125,613160,23419 %19 %Income tax expense

48,1639,052

(l)

57,21518,8948,661

(l)

27,555155 %108 %Net income

$
,924$
22,149$
34,073$
5,727$
,952$
32,679-3 %1 %Diluted earnings per share

$
.18$
.42$
.23$
.41-4 %1 %Diluted weighted average shares outstanding

94,51994,51994,12494,124Selected ratios as a percentage of net salesGross profit

36.0 %38.3 %35.9 %37.6 %Operating expenses

16.6 %15.6 %17.1 %15.6 %Operating income

19.4 %22.6 %18.8 %22.1 %Nine Months EndedConsolidatedMarch 30, 2013March 31, 2012% ChangeGAAPNon-GAAP AdjustmentsAs AdjustedGAAPNon-GAAP AdjustmentsAs AdjustedGAAPAs AdjustedNet sales

$
2,572,594$
-$
2,572,594$
2,341,482$
-$
2,341,48210 %10 %Cost of sales

1,648,79957,146

(a,f)

1,591,6531,539,75568,797

(a,h)

1,470,9587 %8 %Gross profit

923,79557,146980,941801,72768,797870,52415 %13 %Operating expensesDistribution

35,035-35,03529,5
'/>"/>

SOURCE Perrigo Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Perrigo Company To Release Third Quarter Fiscal Year 2013 Results On May 7, 2013
2. Perrigo Company To Present At The Barclays Global Healthcare Conference
3. Perrigo Company To Present At The RBC Global Healthcare Conference
4. Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%
5. Perrigo Company To Present At The Leerink Swann Global Healthcare Conference
6. Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million
7. Perrigo Confirms FDA Approval For Testosterone Gel 1%
8. Perrigo Reports Record Second Quarter Revenue, Adjusted Earnings and Operating Cash Flow
9. Perrigo Company To Acquire OTC Companion Animal Health Company, Velcera, Inc., For $160 Million
10. Perrigo Commences Launch Of Clobetasol Emulsion Propionate Foam, 0.05%
11. Perrigo Company To Release Second Quarter Fiscal Year 2013 Results On February 1, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Phase III Studies With Ofatumumab, Zalutumumab and Zanolimumab, ... (OMX:,GEN) reports today that the last patient to ... in the pivotal Phase III clinical trial,of ofatumumab ... received the last scheduled treatment., In order ...
... Company to Host Conference Call/Webcast at 8:30 a.m. ... May 28 Alfacell Corporation,(Nasdaq: ACEL ) ... from its confirmatory Phase IIIb clinical trial of ... significance for the,primary endpoint of survival in unresectable ...
Cached Medicine Technology:Genmab Announces Updates on Phase III Cancer Studies 2Genmab Announces Updates on Phase III Cancer Studies 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 2Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 4Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 5
(Date:7/9/2014)... been a sharp increase in the number of cancer ... online, interactive service that allows patients to view laboratory ... appointments, and renew prescriptions. , Over a six-year period, ... each year increased five-fold, while the number of total ... a study by Dr. David Gerber , Associate ...
(Date:7/9/2014)... of flatulence and have a reputation for being highly toxic, ... is now being being found to offer potential health benefits ... attacks and dementia. A new compound (AP39), designed and made ... future therapies, by targeting delivery of very small amounts of ... , Scientists in Exeter have already found that the ...
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
(Date:7/9/2014)... diseases has risen dramatically in Western societies. One frequently ... microorganisms and have fewer infections than previous generations, thereby ... by researchers at Sahlgrenska Academy, University of Gothenburg, monitored ... of the immune system in relation to allergic disease. ... the Vstra Gtaland Region, half of them on farms ...
(Date:7/8/2014)... Defense Advanced Research Projects Agency (DARPA) awarded Lawrence ... to develop an implantable neural device with the ... brain to help restore memory, DARPA officials announced ... understanding that memory is a process in which ... information, store it and retrieve it. Certain types ...
Breaking Medicine News(10 mins):Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
... Calif., March 10 ISTA Pharmaceuticals, Inc. (Nasdaq: ... the Cowen and Company 29th Annual Health Care Conference ... 2009, in Boston, MA.ISTA,s President and Chief Executive Officer, ... the Company,s commercial and clinical progress. To access the ...
... 10 Orthocrat, Ltd. announced today that OAD ... OrthoFlow workflow solution. OrthoFlow is designed to save ... exam room to exam room, seeing large volumes of patients ... simply swipes his badge over a reader, and the images ...
... Sahlgrenska Academy, University of Gothenburg, Sweden, shows that three genes ... normally involved in several fundamental processes in the cell. This ... life and principally affect children and young people. , A ... investigated in the work presented in the thesis. This family ...
... Waterlase(TM), DIAGNOdent Laser Technology and the First Comprehensive Dental ... Area residents now have access to the latest ... all in a luxurious spa environment designed for relaxation ... and general dentist, designed her first Northern Westchester location, ...
... The Pew Charitable Trusts today announced that Susan G. Komen ... space in its D.C. headquarters, located at 901 E Street, ... Fenty, Pew has dedicated the vast majority of its building ... first "nonprofit village.""Susan G. Komen for the Cure(R) has been ...
... Health Plan Members Drop Coverage for Multiple Reasons; ... Necessary to Reduce Disenrollment and Improve Balance SheetORLANDO, ... behalf of ConnextionsHealth provides both good and bad ... properly managing member disenrollment delivers a significant, positive ...
Cached Medicine News:Health News:'Swipe Card, See Image': OAD Orthopaedics Improves Clinical Workflow with OrthoFlow 2Health News:Rearrangements of multifunctional genes cause cancer in children and young people 2Health News:High-Tech Meets Luxury at New Dental Practice: Introducing Westchester Smile Design 2Health News:Susan G. Komen for the Cure(R) Signs Lease at Pew's Nonprofit Village 2Health News:Susan G. Komen for the Cure(R) Signs Lease at Pew's Nonprofit Village 3Health News:Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows 2Health News:Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows 3
... generation of Urocap, features automatic ... stopping and printing. The advanced ... with superior low flow rate ... ICS nomenclature normative comparisons to ...
... Stents combine a unique polymer material that ... shape with a chemically bonded wettable solution ... is a stent that satisfies the need ... Lubri-Flex® is available in a wide variety ...
... The Pathfinder Chlamydia Culture ... reliable staining of intracellular ... reticulate bodies) in tissue ... antibody used in this ...
... a direct antigen detection system, that can use ... and monoclonal antibodies to detect RSV directly in ... and reproducibility of monoclonal antibodies with the speed ... are availalbe within 90 minutes. The Pathfinder RSV ...
Medicine Products: